#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Yojana Gadiya"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
 DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
# DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
 DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
 DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
# DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hp-names.belns"
 DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/go-names.belns"
 DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
 DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
 DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
 DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
 DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
 DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
 DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
 DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
 DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
 DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
 DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
 DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
 DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
 DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
 DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
 DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
 DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
 DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "29687724"}

SET Evidence = "Huntington’s disease (HD) is an autosomal dominant
progressive neurogenerative disorder that is characterised
by cognitive, behavioural and motor dysfunction
(see associated Paper 1 on neuropsychiatric manifestations
and diagnosis of HD)."
path(MESH:"Huntington Disease") -- path(MESH:"Neurodegenerative Diseases")
path(MESH:"Huntington Disease") -- path(MESH:"Cognition")
path(MESH:"Huntington Disease") -| bp(GO:"behavior")
path(MESH:"Huntington Disease") -| bp(GO:"motor behavior")

SET Evidence = "Abnormal movements (chorea, dystonia) in HD are due
to changes in neural circuitry and neurotransmitters such
as dopamine."
path(MESH:"Chorea") -- path(MESH:"Huntington Disease")
path(MESH:"Dystonia") -- path(MESH:"Huntington Disease")
path(MESH:"Neural Pathways") -- path(MESH:"Chorea")
path(MESH:"Neural Pathways") -- path(MESH:"Dystonia")
a(CHEBI:"dopamine") -- path(MESH:"Chorea")
a(CHEBI:"dopamine") -- path(MESH:"Dystonia")
path(MESH:"Neural Pathways") -- path(MESH:"Huntington Disease")
path(MESH:"Neural Pathways") -- path(MESH:"Huntington Disease")
a(CHEBI:"dopamine") -- path(MESH:"Huntington Disease")
a(CHEBI:"dopamine") -- path(MESH:"Huntington Disease")

SET Evidence = "In the initial stages, dopamine antagonists
such as risperidone and olanzapine can be used to suppress
the abnormal movements."
#abnrmal movements = chorea, dystonia
a(CHEBI:"risperidone") -| a(CHEBI:"dopamine")
a(CHEBI:"olanzapine") -| a(CHEBI:"dopamine")
a(CHEBI:"risperidone") -| path(MESH:"Chorea")
a(CHEBI:"olanzapine") -| path(MESH:"Chorea")
a(CHEBI:"risperidone") -| path(MESH:"Dystonia")
a(CHEBI:"olanzapine") -| path(MESH:"Dystonia")

SET Evidence = "In April 2017, the FDA
approved the use of deutetrabenazine, a long-acting form
of tetrabenazine, which was successfully found to reduce
chorea in a randomised controlled trial (RCT) of 90
patients (FIRST-HD)."
a(PUBCHEM:73437646) isA a(PUBCHEM:6018)
a(PUBCHEM:73437646) -| path(MESH:"Chorea")

SET Evidence = "Mood disorders: depressive symptoms may predate
the onset of motor symptoms by many
years and can occur throughout the course of the disease."
#disease : HTT
path(MESH:"Depression") -- path(MESH:"Huntington Disease")
path(MESH:"Motor Disorders") -- path(MESH:"Huntington Disease")

SET Evidence = "Some people who are gene positive for HD may
have a primary psychotic disorder such as schizophrenia
that predates their movement disorder for
many years."
path(MESH:"Huntington Disease") -- path(MESH:"Schizophrenia, Disorganized")
path(MESH:"Schizophrenia, Disorganized") -| path(MESH:"Movement")

SET Evidence = "Risperidone may be considered firstline
as it can also suppress the movement disorder."
a(CHEBI:"risperidone") -| path(MESH:"Stereotypic Movement Disorder")

SET Evidence = "There are few large studies using
psychotropic medications in HD-related irritability
and aggression.Mood stabilisers such as valproate
and carbamazepine and selective serotonin reuptake
inhibitors (SSRIs) can be used."
#SSRI : serotonin uptake inhibitors
SET MeSHDisease = "Huntington Disease"
a(CHEBI:"valproate") -| path(MESH:"Irritable Mood")
a(CHEBI:"carbamazepine") -| path(MESH:"Irritable Mood")
a(MESH:"Serotonin Uptake Inhibitors") -| path(MESH:"Irritable Mood")
a(CHEBI:"valproate") -| path(MESH:"Aggression")
a(CHEBI:"carbamazepine") -| path(MESH:"Aggression")
a(MESH:"Serotonin Uptake Inhibitors") -| path(MESH:"Aggression")
UNSET MeSHDisease

SET Confidence = "Obsessive-compulsive
symptoms, repetitive behaviours, inflexibility and
rigidity can also be thought of as part of the frontal
dysexecutive syndrome, and SSRIs and clomipramine
can be used if these are present, though
behavioural strategies are also recommended."
a(MESH:"Serotonin Uptake Inhibitors") -| path(MESH:"Obsessive-Compulsive Disorder")
a(CHEBI:"clomipramine") -| path(MESH:"Obsessive-Compulsive Disorder")

SET Evidence = "The cognitive impairment seen in HD is a form of subcortical
dementia characterised by slowing of thought
processing, executive dysfunction and memory impairment."
#Neurocognitive Disorders : dementia
path(MESH:"Cognitive Dysfunction") -- path(MESH:"Huntington Disease")
path(MESH:"Cognitive Dysfunction") isA path(MESH:"Neurocognitive Disorders")
path(MESH:"Cognitive Dysfunction") -| path(MESH:"Thinking")
path(MESH:"Cognitive Dysfunction") -| path(MESH:"Executive Function")
path(MESH:"Cognitive Dysfunction") -| path(MESH:"Memory")

SET Evidence = "A study of rivastigmine in 11 patients with HD suggested
improvement in motor scores and a trend towards
improvement in cognition and functional scores, but
more study is required.[6]"
SET MeSHDisease = "Huntington Disease"
a(CHEBI:"rivastigmine") -> bp(GO:"motor behavior")
a(CHEBI:"rivastigmine") -> path(MESH:"Cognition")
UNSET MeSHDisease

SET Evidence = "There have been a large number of therapeutic trials
with the aim of improving motor and cognitive symptoms
of HD, targeting the major neurotransmitters
implicated in HD such as amantadine or pridopidine
(glutamate and dopamine antagonists, respectively)."
a(CHEBI:"amantadine") -| a(PUBCHEM:33032)
a(CHEBI:"amantadine") -- path(MESH:"Huntington Disease")
a(PUBCHEM:9795739) -| a(CHEBI:"dopamine")
a(PUBCHEM:9795739) -- path(MESH:"Huntington Disease")

SET Evidence = "Results from 2016
showed that pridopidine did not improve the motor symptoms
of HD; however, there was a statistically significant
improvement in the Total Functional Capacity score,
which could be interpreted as delay in functional decline.[7]"
SET MeSHDisease = "Huntington Disease"
a(PUBCHEM:9795739) cnc bp(GO:"motor behavior")
UNSET MeSHDisease

SET Evidence = "Targeting the glutamate system, amantadine, an NMDAreceptor
antagonist, has had limited success in improving
some of the features of HD."
SET MeSHDisease = "Huntington Disease"
a(CHEBI:"amantadine")  -| p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits")
UNSET MeSHDisease
